Translate AMICOR contents if you like

Saturday, June 27, 2015


Enviado pela AMICOR Bernadete Nonemacher

Nick Finer, MBBS, FRCP; Felipe F. Casanueva, MD, PhD; Walimir F. Coutinho; Luc F. Van Gaal, MD, PhDCME Released: 06/26/2015 ; Valid for credit through 06/26/2016This educational activity is intended for an international audience of non-US healthcare professionals, specifically endocrinologists, diabetologists, primary care physicians, cardiologists, and other healthcare providers involved in the care of patients with overweight and obesity.The goal of this activity is to review the clinical profile of new drug therapies that target physiologic mechanisms to treat patients with obesity.Upon completion of this activity, participants will be able to:Discuss the link between the interrelated global epidemics of obesity and type 2 diabetes, and their links to cardiovascular disease and the benefits of moderate weight lossExplain the physiological interplay between the gut, brain, and fat cells and the multiple hormonal signals, in the context of the physiologic neuroendocrine mechanisms mediating appetite regulation, energy balance, and weight lossEvaluate the rationale for emerging weight loss therapies and the clinical evidence for weight loss, with the prospect of preventing obesity-related comorbidities

No comments: